IDEXX Laboratories (FRA:IX1) Long-Term Debt: €259 Mil (As of Mar. 2026)


FRA:IX1 IDEXX Laboratories Inc FRA:IX1
97 GF Score
Price €500.40
GF Value €555.13
Valuation Modestly Undervalued
View Full Analysis

What is IDEXX Laboratories Long-Term Debt?

IDEXX Laboratories FRA:IX1 +2.86% 97 Long-Term Debt is €259 Mil as of Mar. 2026. GuruFocus rates FRA:IX1 with a GF Score™ of 97/100 and a GF Value™ of €555.13 (Modestly Undervalued).

IDEXX Laboratories's Long-Term Debt for the quarter that ended in Mar. 2026 was €259 Mil.

IDEXX Laboratories's quarterly Long-Term Debt increased from Sep. 2025 (€319 Mil) to Dec. 2025 (€320 Mil) but then declined from Dec. 2025 (€320 Mil) to Mar. 2026 (€259 Mil).

IDEXX Laboratories's annual Long-Term Debt declined from Dec. 2023 (€571 Mil) to Dec. 2024 (€430 Mil) and declined from Dec. 2024 (€430 Mil) to Dec. 2025 (€320 Mil).

IDEXX Laboratories  (FRA:IX1) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

IDEXX Laboratories Long-Term Debt Related Terms

IDEXX Laboratories Long-Term Debt Historical Data

* Premium members only.

The historical data trend for IDEXX Laboratories's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IDEXX Laboratories Long-Term Debt Chart

IDEXX Laboratories Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 686.06 655.50 571.18 429.55 320.12

IDEXX Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 416.06 389.99 319.35 320.12 259.37
FRA:IX1
97GF Score
IDEXX Laboratories Inc FRA:IX1
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of €259 Mil mean?
IDEXX Laboratories (FRA:IX1) has a Long-Term Debt of €259 Mil as of Mar. 2026.
Is IDEXX Laboratories' Long-Term Debt too high?
IDEXX Laboratories' current Long-Term Debt is €259 Mil. Overall, IDEXX Laboratories has a GF Score™ of 97/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does IDEXX Laboratories' Long-Term Debt compare to A and NTRA?
IDEXX Laboratories' Long-Term Debt of €259 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Medical Diagnostics & Research company?
A good Long-Term Debt depends on the Medical Diagnostics & Research industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. IDEXX Laboratories's current Long-Term Debt is €259 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDEXX Laboratories stock overvalued right now?
Based on GuruFocus' analysis, IDEXX Laboratories (FRA:IX1) is currently considered Modestly Undervalued. The stock's GF Value™ is €555.13, compared to a current price of €500.40 — trading 9.9% below its estimated fair value. The current Long-Term Debt is €259 Mil. IDEXX Laboratories' overall GF Score™ is 97/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For IDEXX Laboratories (FRA:IX1), the current Long-Term Debt is €259 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is IDEXX Laboratories (FRA:IX1) Overvalued in 2026?

Based on GuruFocus' analysis, IDEXX Laboratories stock appears to be undervalued. The current stock price of €500.40 is trading 9.9% below its estimated GF Value™ of €555.13. GuruFocus considers IDEXX Laboratories to be Modestly Undervalued.

Key valuation signals for FRA:IX1:

  • Long-Term Debt: €259 Mil
  • GF Value™: €555.13 vs. price of €500.40 (9.9% below fair value)
  • GF Score™: 97/100

No single metric tells the full story. See the FRA:IX1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

IDEXX Laboratories Business Description

Address One IDEXX Drive, Westbrook, ME, USA, 04092
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
97GF Score

Get the complete analysis for FRA:IX1

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€500.40
Price
€555.13
GF Value